638 related articles for article (PubMed ID: 33297563)
1. The Ketamine Antidepressant Story: New Insights.
Alshammari TK
Molecules; 2020 Dec; 25(23):. PubMed ID: 33297563
[TBL] [Abstract][Full Text] [Related]
2. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
4. Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
Cardona-Acosta AM; Bolaños-Guzmán CA
Neuropharmacology; 2023 Mar; 225():109374. PubMed ID: 36516891
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Aleksandrova LR; Phillips AG; Wang YT
J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
[TBL] [Abstract][Full Text] [Related]
7. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
8. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research.
Lv S; Yao K; Zhang Y; Zhu S
Neuropharmacology; 2023 Mar; 225():109378. PubMed ID: 36539011
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of Drugs-The Ketamine Story.
Das J
J Med Chem; 2020 Nov; 63(22):13514-13525. PubMed ID: 32915563
[TBL] [Abstract][Full Text] [Related]
10. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
11. An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions.
Lewis V; Rurak G; Salmaso N; Aguilar-Valles A
Trends Neurosci; 2024 Mar; 47(3):195-208. PubMed ID: 38220554
[TBL] [Abstract][Full Text] [Related]
12. Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect.
Bottemanne H; Berkovitch L; Gauld C; Balcerac A; Schmidt L; Mouchabac S; Fossati P
Neurosci Biobehav Rev; 2023 Nov; 154():105410. PubMed ID: 37793581
[TBL] [Abstract][Full Text] [Related]
13. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Lauterbach EC
Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
[TBL] [Abstract][Full Text] [Related]
14. [A review of the antidepressant properties of ketamine].
Desfossés CY; Blier P
Med Sci (Paris); 2021 Jan; 37(1):27-34. PubMed ID: 33492215
[TBL] [Abstract][Full Text] [Related]
15. Ketamine: Leading us into the future for development of antidepressants.
Carreno FR; Lodge DJ; Frazer A
Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
[TBL] [Abstract][Full Text] [Related]
16. The rapid-onset antidepressant effect of ketamine: More surprises?
Raffa RB; Pergolizzi JV; Taylor R;
J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of ketamine and its metabolites as antidepressants.
Hess EM; Riggs LM; Michaelides M; Gould TD
Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
[TBL] [Abstract][Full Text] [Related]
18. Rodent ketamine depression-related research: Finding patterns in a literature of variability.
Polis AJ; Fitzgerald PJ; Hale PJ; Watson BO
Behav Brain Res; 2019 Dec; 376():112153. PubMed ID: 31419519
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies in major depression: focus on RNAi and ketamine.
Bortolozzi A; Celada P; Artigas F
Curr Pharm Des; 2014; 20(23):3848-60. PubMed ID: 24180396
[TBL] [Abstract][Full Text] [Related]
20. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways.
Ren L
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
